植入式医疗设备开发商UroMems获得6000万美元战略投资-动脉网

UroMems Raises $60 Million Strategic Investment from U.S.ased Ajax Health Fund I

CISION 等信源发布 2026-05-13 23:05



可切换为仅中文







Capital will continue funding pivotal clinical trials and commercial launch preparation of the UroActive

资本将继续为UroActive的关键临床试验和商业上市准备提供资金支持。

System, the first smart automated implant to treat stress urinary incontinence

系统，首个治疗压力性尿失禁的智能自动植入物

GRENOBLE, France and MINNEAPOLIS

格勒诺布尔，法国和明尼阿波利斯

，

May 13, 2026

2026年5月13日

/PRNewswire/ --

UroMems

尿路感染

, a global company developing innovative, implantable mechatronics technology to treat stress urinary incontinence (SUI), today announced it has raised a $60 million strategic investment, the largest fundraising round to date for the company. Ajax Health Fund I

，一家全球性的公司，致力于开发创新的可植入机电技术以治疗压力性尿失禁（SUI），今天宣布已筹集了6000万美元的战略投资，这是该公司迄今为止最大的融资轮。Ajax Health Fund I

financed the entire round, with capital continuing to support large-scale pivotal clinical trials of the UroActive

为整个轮融资提供了资金，资本继续支持UroActive的大规模关键临床试验。

implant in the U.S. and France. The resulting data will pave the way for regulatory submission in multiple countries. UroActive is the first smart automated artificial urinary sphincter (AUS) to treat SUI.

在美国和法国进行植入。所得数据将为多国的监管提交铺平道路。UroActive 是首款用于治疗 SUI 的智能自动化人工尿道括约肌 (AUS)。

'We're excited to fund this pivotal round for UroMems and apply our approach of partnering with potential industry leaders to help build and scale innovative medtech organizations,' said David Beylik, partner at Ajax Health. 'Combining our industry experience and capital with the UroMems team, we believe that the UroActive smart implant has the potential to become the standard of care for SUI treatment.'.

Ajax Health 的合伙人 David Beylik 表示：“我们很高兴为 UroMems 提供这一关键轮次的资金，并运用我们与潜在行业领导者合作的方式，帮助打造和扩展创新的医疗技术公司。通过将我们的行业经验与资金同 UroMems 团队相结合，我们相信 UroActive 智能植入物有潜力成为 SUI 治疗的护理标准。”

The financing will support UroMems through the completion of its ongoing SOPHIA2 clinical trial of the UroActive smart implant in 21 U.S. and French investigational centers in preparation for regulatory submission to both the U.S. and European markets.

这笔资金将支持UroMems完成其正在进行的SOPHIA2临床试验，该试验在21个美国和法国的研究中心测试UroActive智能植入物，以为向美国和欧洲市场提交监管申请做准备。

The latest investment builds upon the momentum of a $47 million Series C financing completed in June 2024, led by Crédit Mutuel Innovation with participation from the European Innovation Council and existing investors Wellington Partners, Bpifrance, Supernova Invest, Hil-Invent, b-to-v Partners and Financière Arbevel..

最新一轮投资是在2024年6月完成的4700万美元C轮融资的基础上进行的，该轮融资由Crédit Mutuel Innovation领投，欧洲创新委员会、现有投资者Wellington Partners、Bpifrance、Supernova Invest、Hil-Invent、b-to-v Partners和Financière Arbevel参与。

'As existing investors, we're thrilled to welcome Ajax Health Fund I to this round,' said Philippe Boucheron, deputy chief of life sciences investments for Bpifrance. 'Based on strong early clinical study results and unprecedented interest from physicians, we've always known that the UroActive System has significant potential to improve patients' lives and disrupt the market.'.

“作为现有投资者，我们很高兴欢迎Ajax Health Fund I参与本轮融资，”法国公共投资银行生命科学投资副主管菲利普·布歇隆表示。“基于早期临床研究结果强劲，且医生们表现出前所未有的兴趣，我们一直都知道UroActive系统具有显著潜力来改善患者生活并颠覆市场。”

'Ajax Health brings additional operating experience as UroActive enters its next stage, and we look forward to working together to support it through approval and commercialization,' said Johannes Fischer, partner at Wellington Partners.

“Well加健康公司在UroActive进入下一阶段时带来了更多的运营经验，我们期待共同努力，支持其通过审批和商业化，”惠灵顿合伙公司的合伙人约翰内斯·费舍尔表示。

UroActive is the first smart active implant that treats SUI, powered by a MyoElectroMechanical System (MEMS). This innovative system is placed around the urethral duct and is controlled based on the patient's activity, without the need for manual adjustments, intending to provide patients with ease of use and a better quality of life than current options.

UroActive 是首款治疗压力性尿失禁（SUI）的智能活性植入物，由肌电机械系统 (MEMS) 驱动。这个创新系统围绕尿道放置，并根据患者的活动进行控制，无需手动调节，旨在为患者提供比现有选择更便捷的使用体验和更好的生活质量。

UroMems has successfully surpassed critical milestones in research and development, clinical outcomes and building the organization..

UroMems 已经成功超越了研发、临床成果和组织建设方面的关键里程碑。

'Ajax Health Fund I's support strengthens our position as we approach the pivotal points of FDA PMA submission and commercialization, and we're grateful for their investment, partnership and confidence in UroActive,' said Hamid Lamraoui, co-founder and chief executive officer of UroMems. 'I believe UroActive will be a game-changer in treating patients suffering from SUI, and we are now one step closer to achieving our shared vision of delivering on the significant unmet need for patients and physicians desperately seeking a better SUI treatment option.'.

“Ajax Health Fund I 的支持在我们接近FDA PMA提交和商业化的关键节点时，进一步巩固了我们的地位，我们非常感谢他们对UroActive的投资、合作和信任，”UroMems的联合创始人兼首席执行官Hamid Lamraoui表示。“我相信UroActive将成为治疗SUI患者的变革者，我们现在离实现共同愿景更近了一步，即满足患者和医生迫切寻求更好的SUI治疗方案的重大未满足需求。”

David Beylik and Dr. Jeremy Durack are joining the UroMems board of directors, each bringing significant strategic expertise to the company. In addition to his partner role at Ajax Health, Beylik served as the founding chief operating officer of Ajax platform Maverix Medical. Prior to Ajax, he was an associate at Latham & Watkins LLP and a law clerk to Chief Justice John Roberts of the U.S.

大卫·贝里克和杰里米·杜拉克博士将加入UroMems董事会，他们各自为公司带来了重要的战略专业知识。除了在Ajax Health担任合伙人角色外，贝里克还曾是Ajax平台Maverix Medical的创始首席运营官。在加入Ajax之前，他是Latham & Watkins律师事务所的助理，并曾担任美国首席大法官约翰·罗伯茨的法律助理。

Supreme Court. Dr. Durack is a practicing interventional radiologist and both a partner and the senior vice president of medical affairs for Ajax Health. Prior to Ajax, he served as vice-chair of radiology at Memorial Sloan Kettering Cancer Center, where his clinical practice and research focused extensively on minimally invasive urology procedures..

最高法院。杜拉克博士是一位执业的介入放射科医生，同时担任Ajax Health的合伙人和医疗事务高级副总裁。在加入Ajax之前，他在纪念斯隆凯特琳癌症中心担任放射科副主任，其临床实践和研究重点广泛集中在微创泌尿外科手术上。

SUI, or involuntary urinary leakage, affects an estimated 40 million Americans and 90 million Europeans. SUI significantly impacts quality of life, as it can be debilitating, and often leads to depression, low self-esteem and social stigma.

压力性尿失禁（SUI），即非自愿性漏尿，影响着约4000万美国人和9000万欧洲人。SUI严重影响生活质量，因为它可能使人虚弱，并常常导致抑郁、自卑和社交污名。

About UroActive

关于UroActive

The UroMems technology platform is protected by more than 200 granted patents and is designed to overcome the limitations of current solutions by optimizing safety and performance, patient experience and surgeon convenience. UroActive is the first active implantable electronic artificial urinary sphincter (AUS) that is being developed to compensate for sphincter insufficiency in patients, both men and women, with SUI.

UroMems技术平台受到200多项已授权专利的保护，旨在通过优化安全性、性能、患者体验和外科医生便利性，克服当前解决方案的局限性。UroActive是首款正在开发中的主动植入式电子人工尿道括约肌（AUS），用于补偿男性和女性压力性尿失禁（SUI）患者的括约肌功能不足。

UroActive has not received marketing authorization from the FDA and is not available for sale in the United States or in the EU. For more information, please visit .

UroActive 尚未获得 FDA 的上市许可，因此在美国和欧盟地区均未上市销售。欲了解更多信息，请访问。

www.uromems.com

。

About Ajax Health

关于Ajax健康

Ajax Health is a U.S.-based private equity firm focused on the medical technology sector. Ajax specializes in forming scaled partnerships with commercial-stage medtech organizations to drive innovation and advance patient outcomes.

Ajax Health是一家总部位于美国的私募股权公司，专注于医疗技术领域。Ajax擅长与商业阶段的医疗技术组织建立规模化合作伙伴关系，以推动创新并改善患者疗效。

Ajax Health Fund I is a fund sponsored by ICONIQ and sub-advised by U.S.-based medtech-focused investment firm Ajax Health.

Ajax健康基金I是由ICONIQ赞助，并由美国医疗技术投资公司Ajax Health担任子顾问的基金。

Media Contact:

媒体联系人:

Shelli Lissick

谢莉·利西克

[email protected]

电子邮件地址

651-276-6922

SOURCE UroMems

来源：UroMems